KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Pfizer (PFE) over the last 6 years, with Q3 2025 value amounting to $924.0 million.

  • Pfizer's Current Deferred Revenue fell 5425.74% to $924.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $924.0 million, marking a year-over-year decrease of 5425.74%. This contributed to the annual value of $1.5 billion for FY2024, which is 4403.7% down from last year.
  • Pfizer's Current Deferred Revenue amounted to $924.0 million in Q3 2025, which was down 5425.74% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Current Deferred Revenue ranged from a high of $6.2 billion in Q4 2022 and a low of $924.0 million during Q3 2025
  • In the last 5 years, Pfizer's Current Deferred Revenue had a median value of $2.5 billion in 2024 and averaged $2.5 billion.
  • Per our database at Business Quant, Pfizer's Current Deferred Revenue surged by 17556.15% in 2021 and then plummeted by 6619.35% in 2023.
  • Pfizer's Current Deferred Revenue (Quarter) stood at $3.1 billion in 2021, then dropped by 17.84% to $2.5 billion in 2022, then grew by 7.14% to $2.7 billion in 2023, then plummeted by 44.04% to $1.5 billion in 2024, then tumbled by 38.85% to $924.0 million in 2025.
  • Its Current Deferred Revenue stands at $924.0 million for Q3 2025, versus $1.1 billion for Q2 2025 and $1.0 billion for Q1 2025.